Industry

Researchers at the AIBN have won vital funding to improve personalised healthcare, develop new energy solutions, and unearth cleaner mining technologies – all in tandem with local industry partners.

Science, for many, is a series of experiments: recreating specific conditions to find the correct answer. But what happens when the lab walls dissolve and a researcher lands in the real world? If Australian Institute for Bioengineering and Nanotechnology PhD candidate Swati Singh learned one thing from Singapore’s vibrant startup culture, it’s that fusing science and business is not only possible, but essential for any budding entrepreneur.

As we close the book on 2022 it is time to look at how far the AIBN has come during the year, and how we are setting ourselves up for an even bigger 2023.

An antiviral surface coating technology sprayed on face masks could provide an extra layer of protection against COVID-19 and the flu.

Needle-free technology, originally developed at the AIBN, has been used to administer a COVID-19 vaccine candidate to successfully protect mice, demonstrating the potential of non-invasive delivery.

Faster-charging and more sustainable batteries with a life up to three times greater than lithium ion are being built with technology developed at AIBN.

A startup company developing technology based on University of Queensland (UQ) research has announced it will partner with the US Government to test its needle-free vaccine delivery technology.

An antibody that could treat immune system disorders could be on the path to clinical trials after securing $20 million in Series A funding.